The Trump administration has announced a new round of 15 drugs selected for Medicare drug pricing. This will reduce costs for $UnitedHealth(UNH)$ , which primarily handles Medicare. This is very bullish as it could increase $UnitedHealth(UNH)$ 's profit margins. These price controls are positive for $UnitedHealth(UNH)$ but negative for $Eli Lilly(LLY)$ and ABBV. How might investors view these developments?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
